Urologix Reports First Quarter Fiscal Year 2015 Results
November 04, 2014 16:00 ET
|
21st North Inc.
Recent Quarter Highlights
Reduced operating expenses 44% compared to the first quarter of the prior year.
Net loss reduced by 67% to $437,000 from a net loss of $1,334,000 in the first...
Urologix Reports Fourth Quarter and Fiscal Year 2014 Results
August 19, 2014 16:00 ET
|
21st North Inc.
Recent Highlights
Urologix restructured the company in April 2014 which reduced cash utilization in the fourth quarter to $98,000
Cost-effectiveness data covering Cooled ThermoTherapyTM...
Urologix Announces Poster Presentation at the 2014 Annual Meeting of the American Urological Association
May 06, 2014 16:05 ET
|
21st North Inc.
The poster "Cost-Effectiveness Markov Model Comparing High- and Low-Energy Transurethral Microwave Therapy for Benign Prostatic Hyperplasia" will be presented Tuesday morning, May 20th, by Dr....
Urologix Reports Fiscal Year 2014 Third Quarter Results
May 06, 2014 16:00 ET
|
21st North Inc.
Third quarter revenue totaled $3.4 million
Cash balance of $816,000 as of March 31, 2014
Annualized expenses reduced by over $4.0 million since January 1, 2014
MINNEAPOLIS, May 6, 2014...
Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Third Quarter of Fiscal Year 2014
April 10, 2014 17:00 ET
|
21st North Inc.
Third quarter revenue totaled $3.4 million
Cash balance of $816 thousand as of March 31, 2014
MINNEAPOLIS, April 10, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc....
Urologix Secures Extension of Credit Facility
February 04, 2014 16:05 ET
|
21st North Inc.
MINNEAPOLIS, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that...
Urologix Reports Fiscal Year 2014 Second Quarter Results
February 04, 2014 16:00 ET
|
21st North Inc.
MINNEAPOLIS, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported...
Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Second Quarter of Fiscal Year 2014
January 08, 2014 16:00 ET
|
21st North Inc.
Second quarter revenue totaled $3.8 million, up 1% sequentially
Cash balance of $1.3M as of December 31, 2013
MINNEAPOLIS, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc....
Urologix Reports Fiscal Year 2014 First Quarter Results
October 29, 2013 16:00 ET
|
21st North Inc.
Executive Summary
First quarter revenue totaled $3.8 million, down 4.8% year-over-year.
Reaffirms fiscal year 2014 total revenue guidance in the range of $15 million to $17...
Urologix Reports Fourth Quarter and Fiscal Year 2013 Results
August 20, 2013 16:00 ET
|
21st North Inc.
Executive Summary
Fiscal year 2013 revenue totaled $16.6 million in-line with the Company's fiscal year guidance range of $16.0 million to $17.0 million.
Fourth quarter revenue totaled...